Literature DB >> 19280165

[Long term treatment of psoriasis with TNF-alpha antagonists. Occurrence of malignant melanoma].

L Kowalzick1, L Eickenscheidt, M Komar, E Schaarschmidt.   

Abstract

A 51-year-old white man developed de novo a cutaneous malignant melanoma (Stage Ia) after a 30-month treatment period with TNF-alpha-antagonists, consecutively using infliximab, adalimumab and etanercept because of a recalcitrant moderate to severe plaque psoriasis. The patient previously had been treated fumarates for 4 years, cyclosporine A for 2 months and methotrexate for 5 weeks. He also received cycles of cream PUVA and UVB before and then between systemic medications. A possible causal connection between development of melanoma and immunosuppressive treatment is discussed in the light of recent literature. The termination of TNF-alpha-antagonist therapy following development of melanoma is recommended.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19280165     DOI： 10.1007/s00105-008-1695-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  11 in total

Review 1.  [Guidelines for cyclosporin therapy in dermatology. Issued by the Consensus Conference on Cyclosporins].

Authors:  U Mrowietz
Journal:  Hautarzt       Date:  2001-03       Impact factor: 0.751

2.  Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.

Authors:  Soko Setoguchi; Daniel H Solomon; Michael E Weinblatt; Jeffrey N Katz; Jerry Avorn; Robert J Glynn; E Francis Cook; Greg Carney; Sebastian Schneeweiss
Journal:  Arthritis Rheum       Date:  2006-09

3.  Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.

Authors:  J Askling; C M Fored; L Brandt; E Baecklund; L Bertilsson; N Feltelius; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

4.  Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies.

Authors:  Gregory J Fulchiero; Heather Salvaggio; Joseph J Drabick; Kevin Staveley-O'Carroll; Elizabeth M Billingsley; James G Marks; Klaus F Helm
Journal:  J Am Acad Dermatol       Date:  2007-05       Impact factor: 11.527

5.  Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.

Authors:  Eliza F Chakravarty; Kaleb Michaud; Frederick Wolfe
Journal:  J Rheumatol       Date:  2005-11       Impact factor: 4.666

6.  Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.

Authors:  Stephen Tyring; Kenneth B Gordon; Yves Poulin; Richard G Langley; Alice B Gottlieb; Meleana Dunn; Angelika Jahreis
Journal:  Arch Dermatol       Date:  2007-06

7.  [Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases].

Authors:  D Lebas; D Staumont-Sallé; E Solau-Gervais; R-M Flipo; E Delaporte
Journal:  Ann Dermatol Venereol       Date:  2007-04       Impact factor: 0.777

Review 8.  Immune regulation in psoriasis and psoriatic arthritis--recent developments.

Authors:  Axel J Hueber; Iain B McInnes
Journal:  Immunol Lett       Date:  2007-09-25       Impact factor: 3.685

Review 9.  From conventional to cutting edge: the new era of biologics in treatment of psoriasis.

Authors:  Julia Tzu; Francisco Kerdel
Journal:  Dermatol Ther       Date:  2008 Mar-Apr       Impact factor: 2.851

10.  Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients--relationships with disease severity.

Authors:  C Bonifati; M Carducci; P Cordiali Fei; E Trento; G Sacerdoti; M Fazio; F Ameglio
Journal:  Clin Exp Dermatol       Date:  1994-09       Impact factor: 3.470
View more
  6 in total

Review 1.  TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review.

Authors:  Ruwaida Ben Musa; Lydia Usha; John Hibbeln; Ece A Mutlu
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

2.  Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.

Authors:  Millie D Long; Christopher F Martin; Clare A Pipkin; Hans H Herfarth; Robert S Sandler; Michael D Kappelman
Journal:  Gastroenterology       Date:  2012-05-11       Impact factor: 22.682

3.  Nodular progression of lentigo malignant melanoma during a treatment with tocilizumab: cause or coincidence?

Authors:  A Finet; M Amini-Adle; B Balme; F Colson; L Thomas
Journal:  Clin Rheumatol       Date:  2012-11-09       Impact factor: 2.980

Review 4.  Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-α blockers and cancer.

Authors:  George Kouklakis; Eleni I Efremidou; Michael Pitiakoudis; Nikolaos Liratzopoulos; Alexandros Ch Polychronidis
Journal:  Drug Des Devel Ther       Date:  2013-03-27       Impact factor: 4.162

5.  Psoriatic arthritis with acral lentiginous melanoma: role for methotrexate?

Authors:  S Rahima; Riyaz Najeeba
Journal:  Indian J Dermatol       Date:  2013-11       Impact factor: 1.494

6.  Dermal Lesions and Skin Cancer in Patients with Inflammatory Bowel Disease Receiving Immunosuppressive Therapy

Authors:  Eftychia Giagkou; Maria Saridi; Eleni Albani; Georgios Gaitanis; Andreas Katsanos; Aris Bechlioulis; Athanasios-Dimitrios Bacasis; Dimitrios K Christodoulou; Konstantinos H Katsanos
Journal:  Asian Pac J Cancer Prev       Date:  2018-10-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.